^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Rectal Cancer

    Related cancers:
    1d
    PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer (clinicaltrials.gov)
    P3, N=382, Not yet recruiting, Sun Yat-sen University
    New P3 trial • pMMR
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • Hetronifly (serplulimab)
    2d
    Identification of locally advanced rectal cancer-related genes based on transcriptome and mendelian randomization analysis with biological validation. (PubMed, Front Immunol)
    Notably, in vitro functional assays of the less-reported gene SLC19A1 demonstrated its role in promoting LARC progression. This study offers new insights into the molecular mechanisms underlying LARC pathogenesis and identifies potential therapeutic targets.
    Journal
    |
    SLC19A1 (Solute Carrier Family 19 Member 1)
    3d
    A core stemness-associated module reveals PLK1, NUF2, KIF23, CDCA8, TOP2A, CENPF, AURKA, and ASPM as key genes in rectal cancer. (PubMed, Eur J Med Res)
    An eight-gene CSC signature captures a stemness-linked G2/M program that generalizes across cohorts, relates to the microenvironment, and is therapeutically tractable via kinase targeting, providing a compact readout for risk stratification and preclinical screening.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • AURKA (Aurora kinase A) • PLK1 (Polo Like Kinase 1) • CDCA8 (Cell Division Cycle Associated 8) • KIF23 (Kinesin Family Member 23)
    3d
    Screening and predictive analysis of common regulatory genes in diabetes and rectal cancer: transcriptional and drug modulation mechanisms. (PubMed, Eur J Med Res)
    Genes such as SYP show significant differential expression in both T2DM and RC and may play significant roles in the progression of T2DM and RC. Transcription factor analysis suggested that SP1 could regulate multiple hub genes. Molecular docking indicated that SP1 is a potential target for active components like stearic acid and EGCG in Ginkgo biloba, highlighting its potential as a therapeutic agent for T2DM and RC.
    Journal
    |
    ER (Estrogen receptor) • CDH3 (Cadherin 3) • SYP (Synaptophysin) • CHGA (Chromogranin A)
    3d
    NEAAR-LARC: Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, University of South Florida | Trial completion date: Jun 2025 --> Jun 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    3d
    Complete remission of advanced MSI-H rectal cancer in a young patient treated with nivolumab: a case report and critical appraisal of the literature. (PubMed, Front Oncol)
    The observed toxicity was consistent with the known toxicity profile of immunotherapy and did not lead to discontinuation of therapy. Our case report highlights the need to test for predictive markers in patients with locoregionally advanced rectal cancer in order to identify specific subtypes of the disease that can be treated with immunotherapy with a high probability of achieving clinical complete remission, thereby avoiding potentially risky surgery.
    Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • MSI-H
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab)
    3d
    ARBOR: Adaptive Radiation Boost for Rectal Cancer (clinicaltrials.gov)
    P1, N=37, Recruiting, Fox Chase Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    4d
    A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas (clinicaltrials.gov)
    P1, N=135, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BI 765049
    8d
    Comparison of Six Different Machine Learning Methods With Traditional Model for Low Anterior Resection Syndrome After Minimally Invasive Surgery for Rectal Cancer -- Development and External Validation of a Nomogram : A Dual-center Cohort Study (clinicaltrials.gov)
    P=N/A, N=3500, Completed, Northern Jiangsu People's Hospital
    New trial
    9d
    Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer (clinicaltrials.gov)
    P2, N=38, Suspended, Rutgers, The State University of New Jersey | Trial completion date: Jan 2026 --> Jan 2028 | Recruiting --> Suspended | Trial primary completion date: Jan 2026 --> Dec 2027
    Trial completion date • Trial suspension • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    9d
    Safety and Efficacy of Serplulimab Combined with Neoadjuvant Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer: A Retrospective Study. (PubMed, Cancer Manag Res)
    All enrolled patients received conventional radiotherapy combined with CapeOX or capecitabine monotherapy, along with serplulimab, followed by TME 8-12 weeks post-nCRT. The combination of serplulimab with nCRT demonstrated safety and efficacy in patients with high-risk pMMR LARC. However, further verification through longer follow-up periods and large-scale prospective studies is warranted.
    Retrospective data • Journal
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    capecitabine • Hetronifly (serplulimab)
    9d
    Response-adapted Total Neoadjuvant Therapy Guided by Induction Chemotherapy in Early- and Intermediate-risk Low Rectal Cancer for Implementation of a Watch-and-wait Strategy (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, West China Hospital
    New trial